Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

Glenmark Pharmaceuticals Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 1.558000
forwardPE 25.131392
debtToEquity 27.943000
earningsGrowth 0.000000
revenueGrowth -0.161000
grossMargins 0.675980
operatingMargins 0.136940
trailingEps 37.050000
forwardEps 42.480000

Glenmark Pharmaceuticals Limited's current ratio of 1.558 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as Glenmark Pharmaceuticals Limited can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
Glenmark Pharmaceuticals Limited's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
GLENMARK's low Debt-to-Equity ratio means it is not excessively reliant on debt financing. This low leverage suggests lower financial risk and stronger equity control, positioning the company in a more stable financial situation and reducing vulnerability to debt-related issues.
Glenmark Pharmaceuticals Limited's low growth in earnings and revenue indicates that profits could shrink. This signals potential financial difficulties for the company, suggesting that its profitability might be under pressure.
Glenmark Pharmaceuticals Limited's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that Glenmark Pharmaceuticals Limited's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

GLENMARK's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


Analysts' buy bias for GLENMARK signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to GLENMARK, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.